99¾Ã¾Ã¾ÃÎÞÂë¹ú²ú

Product Center

²úÎïÖÐÐÄ

µ±Ç°Î»Öãº99¾Ã¾Ã¾ÃÎÞÂë¹ú²ú  >  ²úÎïÖÐÐÄ  >  ºôÎüÓë·Î¹¦ÄÜÑо¿  >  ÎüÈëʽ¸øÒ©¡¢È¾¶¾  >  °Âµþ·¡-850-³¢¶Ù¸ßͨÁ¿¶¯ÎïÈ«Éí±©Â¶ÏµÍ³

¸ßͨÁ¿¶¯ÎïÈ«Éí±©Â¶ÏµÍ³

¼òÒªÃèÊö£ºÈ«Éí±©Â¶È¾¶¾ÏµÍ³£¨Whole-Body Exposure System£©ÊÇÒ»ÖÖÔÚ¶¾Àíѧ¡¢Ò©ÀíѧºÍ»·¾³½¡¿µ¿ÆÑ§Ñо¿Öг£ÓõÄʵÑéÉ豸£¬Ö÷ÒªÓÃÓÚÈÃʵÑ鶯ÎÈçСÊó¡¢´óÊó¡¢ëàÊóµÈ£©Í¨¹ý×ÔÈ»ºôÎü;¾¶£¬È«ÉíÐԵر©Â¶ÓÚÊÜ¿ØÅ¨¶ÈµÄÆøÌ¬¡¢ÕôÆû̬»òÆøÈܽºÌ¬µÄÊÜÊÔÎïÖÊÖС£

  • ²úÎïÐͺţºWBE-850-LD
  • ³§ÉÌÐÔÖÊ£ºÉú²ú³§¼Ò
  • ¸üÐÂʱ¼ä£º2025-11-13
  • ·Ã&²Ô²ú²õ±è;&²Ô²ú²õ±è;ÎÊ&²Ô²ú²õ±è;&²Ô²ú²õ±è;Á¿£º270

Ïêϸ½éÉÜ

Æ·ÅÆËþÍû¿Æ¼¼¼Û¸ñÇø¼äÃæÒé
²úµØÀà±ð¹ú²úÓ¦ÓÃÁìÓòÒ½ÁÆÎÀÉú,»·±£,ÖÆÒ©/ÉúÎïÖÆÒ©,×ÛºÏ

²úÎïÃèÊö  

È«Éí±©Â¶È¾¶¾ÏµÍ³£¨Whole-Body Exposure System£©ÊÇÒ»ÖÖÔÚ¶¾Àíѧ¡¢Ò©ÀíѧºÍ»·¾³½¡¿µ¿ÆÑ§Ñо¿Öг£ÓõÄʵÑéÉ豸£¬Ö÷ÒªÓÃÓÚÈÃʵÑ鶯ÎÈçСÊó¡¢´óÊó¡¢ëàÊóµÈ£©Í¨¹ý×ÔÈ»ºôÎü;¾¶£¬È«ÉíÐԵر©Â¶ÓÚÊÜ¿ØÅ¨¶ÈµÄÆøÌ¬¡¢ÕôÆû̬»òÆøÈܽºÌ¬µÄÊÜÊÔÎïÖÊÖС£Óë½ö±©Â¶ºôÎüµÀµÄ±Ç±©Â¶È¾¶¾ÏµÍ³ (Nose-only exposure system) Ïà±È£¬È«Éí±©Â¶È¾¶¾ÏµÍ³ÔÊÐíÊÜÊÔ¶¯ÎïµÄÕû¸öÉíÌ壨°üÀ¨Æ¤·ôºÍë·¢£©¶¼±©Â¶ÓÚȾ¶¾»·¾³ÖС£

1¡¢Ä£ÄâÕæÊµ±©Â¶³¡¾°£ºÈ«Éí±©Â¶È¾¶¾ÏµÍ³¸ü½Ó½üÓÚÄ£ÄâÈËÀà»ò¶¯ÎïÔÚʵ¼Ê»·¾³ÖпÉÄÜÓöµ½µÄ±©Â¶Çé¿ö£¬ÀýÈç¿ÕÆøÎÛȾ¡¢»¯Ñ§Æ·Ð¹Â©»òÒ©ÎïÎí»¯µÈ¡£Í¨¹ýÈ«Éí±©Â¶£¬¿ÉÒÔÑо¿ÎÛȾÎïͨ¹ýºôÎüµÀ¡¢Æ¤·ôµÈ¶àÖÖ;¾¶½øÈëÌåÄÚµÄ×ÛºÏЧӦ ¡£

2¡¢Ñо¿¶àÖÖ±©Â¶Í¾¾¶µÄ×ÛºÏÓ°Ï죺ÎüÈëµÄÎïÖʲ»½öÓ°ÏìºôÎüµÀ£¬»¹»á½øÈëѪҺѭ»·£¬µ½´ïÆäËû°ÐÆ÷¹Ù£¨ÈçÐÄѪ¹Üϵͳ¡¢Éñ¾­ÏµÍ³¡¢¸ÎÔà¡¢ÉöÔàµÈ£©¡£È«Éí±©Â¶ÄܸüÈ«ÃæµØÆÀ¹ÀÊÜÊÔÎïµÄϵͳÐÔ¶¾ÐÔ¡£

²úÎïÌØµã  

1¡¢¶àÎïÖʼæÈÝÐÔ£º

ÊÊÓÃÓÚ¶àÖÖÀàÐ͵ÄȾ¶¾ÎïÖÊ£¬Èç±Ê²Ñ2.5Àà¿ÅÁ£Îï¡¢ÏãÑÌÑÌÎí¡¢³Õ°¿°ä²õÓлúÈܼÁÆøÈܽº¡¢ÒºÌåÎí»¯ÆøÈܽº¡¢¼×ÍéµÈÆøÌ壬ÒÔ¼°·Û³¾¡¢ÄÉÃ׿ÅÁ£¡¢»¨·ÛµÈ£¬Âú×㲻ͬÑо¿ÐèÇó¡£

2¡¢»·¾³²ÎÊý¿ØÖÆÓë¼à²â£º

Å䱸*µÄ¿ØÖÆÏµÍ³£¬¿Éʵʱ¼à²âºÍÏÔʾȾ¶¾¹ñÄÚµÄζȡ¢Êª¶È¡¢Ñ¹Á¦¡¢ÑõÆøÅ¨¶È¡¢¶þÑõ»¯Ì¼Å¨¶È¡¢Ò©ÎïŨ¶ÈµÈ»·¾³²ÎÊý£¬È·±£ÊµÑé»·¾³Îȶ¨ÇÒ·ûºÏʵÑéÒªÇó¡£Í¨¹ýÆøÌåÁ÷Á¿¿ØÖÆÏµÍ³±£Ö¤È¾¶¾Å¨¶ÈµÄ׼ȷÐÔºÍÎȶ¨ÐÔ¡£

3¡¢Êý¾Ý¼Ç¼Óë×·ËÝ£º

Äܹ»¼Ç¼ʵÑé¹ý³ÌÖеĸ÷ÖÖÊý¾Ý£¬°üÀ¨»·¾³²ÎÊý±ä»¯¡¢È¾¶¾Ê±¼ä¡¢¶¯Îï·´Ó¦µÈ£¬·½±ãÑо¿ÈËÔ±ËæÊ±²éÔĺͷÖÎö¡£ÕâЩÊý¾Ý¶ÔÓÚÆÀ¹ÀʵÑé½á¹û¡¢×ܽáʵÑ鹿ÂÉÒÔ¼°ºóÐøµÄÑо¿¶¼¾ßÓÐÖØÒª¼ÛÖµ¡£

4¡¢·ÏÆø´¦Àí£º

´øÓиßЧµÄ·ÏÆø´¦Àíϵͳ£¬¿ÉÓÐЧ¹ýÂ˺;»»¯ÊµÑé²úÉúµÄ·ÏÆø£¬½«ÆäÖеÄÓк¦ÎïÖÊÈ¥³ý»ò½µµÍµ½°²È«Ë®Æ½£¬·ÀÖ¹ÎÛȾʵÑéÊÒ»·¾³ºÍΣº¦ÊµÑéÈËÔ±½¡¿µ¡£

5¡¢³§±«³§304²»Ðâ¸Ö²ÄÖÊ£º

¹ñÌå²ÉÓ󧱫³§304²»Ðâ¸Ö²ÄÁÏÖÆ³É£¬¾ßÓÐÁ¼ºÃµÄÃÜ·âÐÔºÍÄ͸¯Ê´ÐÔ£¬¿É·ÀֹȾ¶¾ÆøÌåй©¡£

6¡¢µÆ¹â¿ØÖÆ£º

ÄÚÖó¢·¡¶ÙµÆ£¬Ö§³ÖÊÖ¶¯¿ª¹Ø¡£ÊµÑéʱ£¬¿ªÆôµÆ¹â¿ÉÇåÎúÕÕÁÁ²ÕÄÚ£¬±ãÓڹ۲춯ÎïÐÐΪ¡¢È¾¶¾·´Ó¦£»ÈôÐèÄ£ÄâÌØ¶¨»·¾³£¨ÈçÖçÒ¹½ÚÂÉÑо¿£©£¬¹Ø±ÕµÆ¹âÓªÔì°µ»·¾³£¬ÎªÊµÑ鳡¾°¶¨ÖÆ»¯Ìṩ»ù´¡¡£

7¡¢×ÏÍâÏûɱ£º

ʵÑéºó£¬¿ªÆôÄÚÖÃ×ÏÍâµÆ£¬ÀûÓÃ×ÏÍâÏßǿɱ¾úÄÜÁ¦£¬¶Ô²ÕÄÚ¿Õ¼ä½øÐÐÏûɱ¡£¿ÉÓÐЧɱÃð²ÐÁô²¡Ô­Ì塢΢ÉúÎ±ÜÃâ½»²æÎÛȾ£¬ÎªÏÂÒ»´ÎʵÑéÓªÔì½à¾»»·¾³¡£

8¡¢ÊÓÆµ¼à¿Ø£º

¾ß±¸ÊµÊ±¹Û²ìÓë»Ø·Å¹¦ÄÜ¡£Óû§¿ÉËæÊ±²é¿´²ÕÄÚ¶¯Îï״̬£¬¼Ç¼Ⱦ¶¾¹ý³ÌÖж¯Îï»î¶¯¡¢Òì³£·´Ó¦µÈ£»¾«×¼²¶×½Ï¸Î¢ÉúÀíÐÐΪ±ä»¯£¬ÎªÊý¾Ý·ÖÎö²¹³äÖ±¹ÛÒÀ¾Ý£¬ÈÃʵÑé¡°¹ý³Ì¿É×·ËÝ¡¢Ï¸½Ú²»ÒÅ©"¡£

9¡¢¾¯±¨µÆ£º

¿ÉÉèÖñ¨¾¯²ÎÊý£¨ÈçȾ¶¾Å¨¶ÈãÐÖµ¡¢ÎÂʪ¶ÈÒì³£ÖµµÈ£©¡£µ±²ÕÄÚ»·¾³»òȾ¶¾²ÎÊý´¥¼°É趨ֵ£¬¾¯±¨µÆÉÁ˸²¢ÃùµÑ£¬µÚһʱ¼äÌáÐÑ¿ÆÑÐÈËÔ±¸ÉÔ¤¡£

10¡¢ÅçÁÜϵͳ£º

ʵÑé½áÊøºó£¬Íâ½ÓˮԴ¼´¿ÉÆô¶¯£¬¶Ô²ÕÄÚ½øÐгåÏ´¡£Õë¶ÔȾ¶¾²ÐÁô¡¢¶¯ÎïÅÅйÎïµÈ£¬¿ìËÙÇå½à²ÕÌ壬¼õÉÙÈ˹¤Ë¢Ï´¸ºµ£¡£


²»Ðâ¸ÖÍø¸ñ±©Â¶Áý

¸ßͨÁ¿¶¯ÎïÈ«Éí±©Â¶ÏµÍ³

ÊÊÓÃÁìÓò

¶¾ÀíѧÑо¿µÄºËÐŤ¾ß£º

ÆÀ¹ÀÎüÈë¶¾ÐÔ£º È·¶¨»¯Ñ§ÎïÖÊ¡¢Ò©Æ·¡¢ÄÉÃ׿ÅÁ£¡¢¹¤ÒµÔ­ÁÏ¡¢¿ÕÆøÎÛȾÎïµÈͨ¹ýÎüÈë;¾¶µÄ¼±ÐÔ¡¢ÑÇÂýÐÔ¡¢ÂýÐÔ¶¾ÐÔ£¨°üÀ¨ÖÂËÀÐÔ¡¢Æ÷¹ÙËðÉË¡¢Ö°©ÐԵȣ©¡£

½¨Á¢¼ÁÁ¿-·´Ó¦¹ØÏµ£º ͨ¹ý¿ØÖƱ©Â¶Å¨¶ÈºÍʱ¼ä£¬¾«È·Ñо¿±©Â¶Ë®Æ½Óë¶¾ÐÔЧӦÖ®¼äµÄ¹ØÏµ£¬ÎªÖƶ¨°²È«ÏÞÖµ£¨ÈçÖ°Òµ±©Â¶ÏÞÖµ¡¢»·¾³¿ÕÆøÖÊÁ¿±ê×¼£©Ìṩ¹Ø¼ü¿ÆÑ§ÒÀ¾Ý¡£

×÷ÓûúÖÆÑо¿£º Ñо¿ÎÛȾÎïÈçºÎͨ¹ýºôÎüµÀ½øÈëÌåÄÚ¡¢ÔÚÌåÄÚµÄÎüÊÕ¡¢·Ö²¼¡¢´úл¡¢ÅÅй¹ý³Ì£¨ADME£©£¬ÒÔ¼°ÓÕ·¢Ñ×Ö¢¡¢Ñõ»¯Ó¦¼¤¡¢»ùÒòËðÉ˵ȶ¾ÐÔ»úÖÆ¡£

¿ÕÆøÎÛȾ½¡¿µÐ§Ó¦Ñо¿£º

Ñо¿³ÇÊдóÆøÎÛȾÎÈç½»Í¨Î²Æø¡¢¹¤ÒµÅÅ·ÅÎ¡¢ÊÒÄÚ¿ÕÆøÎÛȾÎÈç¶þÊÖÑÌ¡¢Åëâ¿ÓÍÑÌ¡¢¼×È©£©¡¢Ìض¨Óк¦ÆøÌ壨Èç°±Æø¡¢Áò»¯Ç⣩µÈ¶ÔºôÎüϵͳ¼²²¡£¨Ïø´­¡¢°ä°¿±Ê¶Ù£©¡¢ÐÄѪ¹Ü¼²²¡¡¢Éñ¾­ÍËÐÐÐÔ¼²²¡µÈµÄÓÕ·¢»ò¼ÓÖØ×÷Óá£

Ö°ÒµÓë»·¾³½¡¿µ·çÏÕÆÀ¹À£º

ÆÀ¹ÀÌØ¶¨¹¤×÷³¡Ëù£¨È绯¹¤³§¡¢¿óɽ¡¢·Û³¾»·¾³£©Öй¤ÈË¿ÉÄܽӴ¥µÄ»¯Ñ§ÎïÖʵķçÏÕ¡£

ÆÀ¹À»·¾³ÎÛȾÎï¶ÔÈËȺ£¨ÌرðÊÇÃô¸ÐÈËȺÈç¶ùͯ¡¢ÀÏÈË£©µÄDZÔÚ½¡¿µ·çÏÕ¡£

Ïà¶ÔÕæÊµµØÄ£ÄâȺÌ屩¶»·¾³£º

¶¯ÎïÔÚÇ»ÊÒÄÚ¿ÉÒÔÏà¶Ô×ÔÓɻ£¬ÐÐΪ£¨ÈçÊáÀíë·¢£©¿ÉÄÜÓ°Ï챩¶£¨ÈçÆ¤·ô½Ó´¥¡¢¾­¿ÚÉãÈ룩£¬ÕâÔÚÒ»¶¨³Ì¶ÈÉÏÄ£ÄâÁËÕæÊµ»·¾³ÖжàÖÖ±©Â¶Í¾¾¶²¢´æµÄÇé¿ö£¨¾¡¹ÜÓÐʱÐè񻂿·ÖÖ÷´Î£©¡£

¸ßЧÐÔ£¨Ïà¶ÔÓÚ¸öÌ屩¶£©£º

Ò»¸ö±©Â¶Ç»¿ÉͬʱÈÝÄɶàÖ»¶¯Îï½øÐб©Â¶£¬Ìá¸ßÁËʵÑéЧÂÊ£¬ÓÈÆäÊÊÓÃÓÚÐèÒª½Ï´óÑù±¾Á¿µÄÂýÐÔÑо¿¡£

ÐͺÅ˵Ã÷

Ãû³Æ

ÐͺÅ

˵Ã÷

µ¥Î»

¸ßͨÁ¿¶¯ÎïÈ«Éí±©Â¶ÏµÍ³

WBE-850-LD


u±êÅäÒºÌ寸Èܽº·¢ÉúÆ÷ºÍ¸É·ÛÆøÈܽº·¢ÉúÆ÷

uÈÝÄÉ9¸ö±©Â¶Áý

u±©Â¶²ÕÍâ³ß´ç£¨°Â¡Á¶Ù¡Á±á£©£º1600³æ800³æ1800³¾³¾

uÖØÁ¿Ô¼£º200°ì²µ


Ì×



²Î¿¼ÎÄÏ×


[1]Fan Z,Zhou B,Liu Y,Sun W,Fang Y,Lu H,Chen D,Lu K,Wu X, Xiao T, Xie W, Bian Q."Optimization and Application of an Efficient and Stable Inhalation Exposure System for Rodents".[J].AAPS PharmSciTech.2022 Jan 6;23(1):50. doi:10.1208/s12249-021-02191-8.

[2]Jushan Zhang,Mo Xue,Rong Pan,Yujie Zhu,Zhongyang Zhang,Haoxiang Cheng,Johan L M Bj?rkegren,Jia Chen,Zhiqiang Shi,Ke Hao"An e-cigarette aerosol generation, animal exposure and toxicants quantification system tocharacterize in vivo nicotine kinetics in arterial and venous blood"[J].bioRxiv preprint doi.

[3]Guolin Zhao,William Ho,Jinxian Chu, Xiaojian Xiong, Bin Hu,Kofi Oti Boakye-Yiadom,Xiaoyang Xu,Xue-Qing Zhang,Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of KRAS-Mutant Non-Small-Cell Lung Cancer,[J]ACS Applied Materials&Interfaces,2023-06-24,DOI:10.1021/acsami.3c05007.

[4]Liu X, Zhao L, Wang R, et al. TRPM2 exacerbates airway inflammation by regulating oxidized-CaMK¢ò in allergic asthma[J]. Heliyon, 2024, 10(1): e23634.

[5]Tian X, Gao Y, Ma W, et al. Establishment of an Inhalation Administration Non-invasive Murine Model for Rapidly Testing Drug Activity against Mycobacterium tuberculosis[J]. bioRxiv, 2024: 2024.02. 27.582260.

[6]Liu L, Tang Z, Zeng Q, et al. Transcriptomic Insights into Different Stimulation Intensity of Electroacupuncture in Treating COPD in Rat Models[J]. Journal of Inflammation Research, 2024: 2873-2887.

[7]Dong Y, Dong Y, Zhu C, et al. Targeting CCL2-CCR2 signaling pathway alleviates macrophage dysfunction in COPD via PI3K-AKT axis[J]. Cell Communication and Signaling, 2024, 22(1): 364.

[8]Shen S, Huang Q, Liu L, et al. GATA2 downregulation contributes to pro-inflammatory phenotype and defective phagocytosis of pulmonary macrophages in chronic obstructive pulmonary disease[J]. Aging (Albany NY), 2024, 16(19): 12928.

[9]Zou X, Huang Q, Kang T, et al. An integrated investigation of mitochondrial genes in COPD reveals the causal effect of NDUFS2 by regulating pulmonary macrophages[J]. Biology Direct, 2025, 20(1): 4.

[10]Tian X, Gao Y, Li C, et al. A novel non-invasive murine model for rapidly testing drug activity via inhalation administration against Mycobacterium tuberculosis[J]. Frontiers in Pharmacology, 2025, 15: 1400436.

[11]Liu K, Liu R, Zhang C, et al. Suzi Daotan Decoction alleviates asthmatic airway remodeling through the AMPK/SIRT1/PGC-1¦Á signaling pathway and PI3K/AKT signaling pathway[J]. Scientific Reports, 2025, 15(1): 6690.

[12]Huang Q, Kang T, Shen S, et al. Extracellular vesicular delivery of ceramides from pulmonary macrophages to endothelial cells facilitates chronic obstructive pulmonary disease[J]. Cell Communication and Signaling, 2025, 23(1): 124.

[13]Zeng H, Liu X, Liu P, et al. Exercise's protective role in chronic obstructive pulmonary disease via modulation of M1 macrophage phenotype through the miR-124-3p/ERN1 axis[J]. Science Progress, 2025, 108(3): 00368504251360892.




´Ë½éÉܼ°²ÎÊýΪ²úÎï»ù´¡ÐÅÏ¢£¬¿ÉÄÜÖͺóÓÚ²úÎï¸üУ¬¾ßÌå²ÎÊýÇëÓëÎÒ˾ÁªÏµ¡£



²úÎï×Éѯ

ÁôÑÔ¿ò

  • ²úÎ

  • ÄúµÄµ¥Î»£º

  • ÄúµÄÐÕÃû£º

  • ÁªÏµµç»°£º

  • ³£ÓÃÓÊÏ䣺

  • Ê¡·Ý£º

  • ÏêϸµØÖ·£º

  • ²¹³ä˵Ã÷£º

  • ÑéÖ¤Â룺

    ÇëÊäÈë¼ÆËã½á¹û£¨Ìîд°¢À­²®Êý×Ö£©£¬È磺Èþ¼ÓËÄ=7
021-51537683
»¶Ó­ÄúµÄ×Éѯ
ÎÒÃǽ«½ß¾¡È«Á¦ÎªÄúÓÃÐÄ·þÎñ
502153910
¹Ø×¢Î¢ÐÅ
°æÈ